This company listing is no longer active
ATE Stock Overview
A biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Antibe Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.29 |
| 52 Week High | CA$1.23 |
| 52 Week Low | CA$0.15 |
| Beta | 0.19 |
| 1 Month Change | 0% |
| 3 Month Change | -69.59% |
| 1 Year Change | -42.16% |
| 3 Year Change | -93.01% |
| 5 Year Change | -90.92% |
| Change since IPO | -94.64% |
Recent News & Updates
Recent updates
Is Antibe Therapeutics (TSE:ATE) In A Good Position To Invest In Growth?
Dec 15
We Think Antibe Therapeutics (TSE:ATE) Needs To Drive Business Growth Carefully
Mar 20Antibe Therapeutics (TSE:ATE) Is In A Strong Position To Grow Its Business
Oct 16Antibe Therapeutics Inc.'s (TSE:ATE) Profit Outlook
Feb 11We're Keeping An Eye On Antibe Therapeutics' (TSE:ATE) Cash Burn Rate
Jan 07
Auditors Are Concerned About Antibe Therapeutics (CVE:ATE)
Jul 31Need To Know: The Consensus Just Cut Its Antibe Therapeutics Inc. (CVE:ATE) Estimates For 2021
Jul 29Shareholder Returns
| ATE | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -3.8% | -0.1% |
| 1Y | -42.2% | -46.8% | 16.7% |
Return vs Industry: ATE underperformed the Canadian Pharmaceuticals industry which returned 42.8% over the past year.
Return vs Market: ATE underperformed the Canadian Market which returned 12.5% over the past year.
Price Volatility
| ATE volatility | |
|---|---|
| ATE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 12.3% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: ATE's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ATE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 11 | Dan Legault | www.antibethera.com |
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company’s pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain.
Antibe Therapeutics Inc. Fundamentals Summary
| ATE fundamental statistics | |
|---|---|
| Market cap | CA$15.64m |
| Earnings (TTM) | -CA$18.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs ATE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATE income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$18.24m |
| Earnings | -CA$18.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/28 09:25 |
| End of Day Share Price | 2024/04/08 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Antibe Therapeutics Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sally Yanchus | Brookline Capital Markets |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Robert Goff | Echelon Wealth Partners Inc. |